Second-line Chemotherapy with Paclitaxel and Carboplatin for Patients with Recurrent Ovarian Carcinoma.
- Author:
Hyung Joo SEO
1
;
Chul Min LEE
;
Jaung Sun KIM
;
Hye Joo LEE
;
Yong Joo PARK
;
Yong Kyoon CHO
;
Hoon CHOI
;
Bok Rin KIM
;
Hong Kyoon LEE
Author Information
1. Department of Obstetrics and Gynecology, Inje University, Sanggye Paik Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Paclitaxel;
Salvage therapy;
Recurrent ovarian carcinoma
- MeSH:
Anemia;
Area Under Curve;
Carboplatin*;
Drug Therapy*;
Drug Therapy, Combination;
Humans;
Ovarian Neoplasms;
Paclitaxel*;
Recurrence;
Salvage Therapy
- From:Korean Journal of Obstetrics and Gynecology
2004;47(10):1915-1920
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study is to investigate the efficacy and toxicity of paclitaxel plus carboplatin used as a salvage therapy. METHODS: Between June 2000 and November 2003, 10 patients aged 43-74 (median 55.0) with recurrent ovarian carcinoma were given combination chemotherapy including paclitaxel and carboplatin. The subjects received initial chemotherapy with paclitaxel plus cisplatin/carboplatin. On recurrence, paclitaxel was administered intravenously at a dose of 175 mg/m2 with carboplatin by AUC 5 every 3 weeks. The median treatment cycle was 10 cycles (range, 1 to 15 cycles). Recurrence of ovarian carcinoma was determined by elevation of serum CA-125, or radiologic imaging. Responses and toxicities were evaluated according to Gynecologic Oncology Group criteria and Common Terminology Criteria for Adverse Events from NCI (National Cancer Institute). RESULTS: The overall clinical response rate was 60.0% (6/10). Better response was observed in patients who were sensitive with initial chemotherapy. Anemia was the most frequent complication. CONCLUSION: Paclitaxel and carboplatin has been shown to be a feasible agent in patients with recurrent ovarian cancer.
